Abstract. – BACKGROUND: Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death among females owing.

AIM: This study aimed to construct a kind of PEG-coated irinotecan cationic liposomes for investigating its efficacy and mechanism of action in the treatment of breast cancer in preclinical models.

MATERIALS AND METHODS: Evaluations were performed on the MDA-MB231 breast cancer cells, the xenografted MDA-MB231 cancer cells in Female nude mice and Sprague-Dawley (SD) rat. The liposomes were characterized through assays of cytotoxicity, intracellular uptake, nucleim orphology, antitumor activities, pharmacokinetics and tissue distribution.

RESULTS: The zeta potential of PEG-coated irinotecan cationic liposomes was approximately 23 mV. The PEG-coated irinotecan cationic liposomes were approximately 66nm in diameter, significantly increased the intracellular uptake of irinotecan, and showed strong inhibitory effect on MDA-MB231 breast cancer cells. A significant antitumor efficacy in the xenografted MDA-MB231 breast cancer cells in nude mice was evidenced by intravenous administration of PEG-coated irinotecan cationic liposomes. PEG-coated irinotecan cationic liposomes also improved the irinotecan blood circulation time and showed an enhanced drug concentration in tumor.

CONCLUSIONS: PEG-coated irinotecan cationic liposomes had significant inhibitory effect against breast cancer in vitro and in vivo, hence providing a new strategy for treating breast cancer.

Key Words:
Breast cancer, PEG-coated irinotecan cationic liposomes, Pharmacokinetics, Tissue distribution, HPLC.

Introduction

Breast cancer is one of the most frequent cancers among women worldwide. It is a disease that can affect women of various ages where the risk of developing breast cancer increases with age. Approximately one in eight women will be diagnosed with breast cancer during their lifetime. As a consequence, there is a great need to develop a treatment strategy that can successfully reduce the incidence of breast cancer and prolong the life of affected women.

Irinotecan (CPT-11), a water-soluble camptothecin, is commonly in clinical used for the cancer treatment. It exerts anti-tumor activity by inhibiting the intranuclear enzyme topoisomerase I. In tumor cells, the level of topoisomerase I enzyme is higher than in normal cells. Irinotecan was shown to exert its cytotoxic activity through inhibition of DNA replication while acting upon DNA topoisomerase I enzyme. DNA topoisomerase relieves the torsional stress that develops during DNA replication by inducing single strand breaks. The irinotecan binds to the topoisomerase I-DNA complex, thereby leading to replication arrest and the formation of double-strand DNA breaks which, while not repaired, can lead to the cancer cell death. However, the main adverse effects of irinotecan in humans are gastrointestinal toxicity and myelosuppression which limits its usage and administration.

Liposomes have been widely used in the therapeutic drug delivery to enhance permeability and retention (EPR) effects in tumor tissues and reduce systemic side effect of anticancer agent, including small molecular drugs, proteins, genes (DNA or RNA) and diagnostic contrast reagents. PEGylated lipids (PEG2000-DSPe) can inhibit opsonization by plasma proteins and contribute longer circulation for liposome because of the “steric stabilization” effect. With the surface hydrophilic protective layer from PEG chain, PEGylated liposome showed characterizations of more stability, sustained release, prolonged blood circulation time and reduced reticuloendothelial system uptake.

Although liposomes have been successfully applied in the clinic, further efforts on the component optimization are still a hot topic in the re-
The objectives of the present study are to prepare polyethylene glycol (PEG)-coated irinotecan cationic liposomes by incorporating octadecylamine into the lipophilic bilayer, as shown in Figure 1A. Irinotecan was entrapped into the aqueous cores by ammonium sulfate gradient method in order to get high encapsulation efficiency. The aim of present study was to explore the preparation of PEG-coated irinotecan cationic liposomes, to define the action mechanisms, to evaluate the efficacy in treating of breast cancer, and to evaluate the pharmacokinetics and distrib-

![Figure 1. A. Schematic representations of two liposomal constructs consisting of PEG-coated irinotecan cationic liposomes and PEG-coated irinotecan liposomes. B. Size distribution of PEG-coated irinotecan cationic liposomes by dynamic light scattering (DLS) analysis. C. The release profiles of irinotecan from two different liposomes in PBS solution containing 10% serum protein at 37°C respectively. Data are presented as the mean ± SD (n=3).](image-url)
PEG-coated irinotecan cationic liposomes improve the therapeutic efficacy of breast cancer in animals

Materials and Methods

Preparation of PEG-Coated Irinotecan Cationic Liposomes

PEG-coated irinotecan cationic liposomes were prepared as previously described. Soybean phosphatidylcholine (SPC) (Sigma-Aldrich Corporation, Beijing local agent, China), cholesterol (Sigma-Aldrich Corporation, Beijing local agent, China), polyethylene glycol-distearoylphosphatidylethanolamine (PEG2000-DSPE, Avanti Polar Lipids, Alabaster, AL, USA) and octadecylamine (Johnson Matthey Company, London, UK) (54/23/4/2.5, µmol ratio) were dissolved in chloroform in a pear-shaped flask. The chloroform was evaporated to dryness under vacuum with a rotary evaporator, and then the formed lipid film was hydrated with 250 mM ammonium sulfate by sonication in the water bath for 5 min, followed by sonication using a probe-type sonicator for 10 min. The suspensions after hydration were successively extruded through polycarbonate membranes (Millipore, Bedford, MA, USA) with the pore size of 400 nm, and 200 nm for 3 times, respectively. Afterwards, the blank PEG-coated cationic liposomes were obtained19.

To prepare PEG-coated irinotecan cationic liposomes, the blank PEG-coated cationic liposomes were then dialyzed (8,000-15,000 molecular mass cutoff) (Beijing Dingguo Biotechnology Limited Company, China) in the 500 ml physiological saline (0.9% NaCl) for two times. Irinotecan was loaded using an ammonium sulfate gradient loading method, as reported previously. Appropriate amounts of irinotecan hydrochloride (Jiangsu Henrui Medicine Corporation, China) were added to the blank PEG-coated cationic liposomes. After mixing, the suspensions were incubated at 50 °C in water bath, and intermittently shaken for 30 min to produce the PEG-coated irinotecan cationic liposomes.

Characterization of PEG-coated Irinotecan Cationic Liposomes

PEG-coated irinotecan cationic liposomes and PEG-coated irinotecan liposomes were passed over a Sephadex G-50 column (Sigma-Aldrich Corporation, Beijing local agent, China) to remove the free irinotecan. The encapsulation efficiency of irinotecan was calculated with the formula: $EE = \left(\frac{W_{\text{encap}}}{W_{\text{total}}}\right) \times 100\%$, where $EE$ is the encapsulation efficiency of irinotecan, and $W_{\text{encap}}$ is the measured amount of irinotecan in the liposomal suspensions after passing over the column. The irinotecan concentration was determined by using fluorospectrophotometer.

In vitro release of irinotecan in the liposomes was performed by the dialysis against the release medium containing serum protein (phosphate buffered saline containing 10% fetal calf serum). A volume of 2.5 ml liposomes plus 2.5 ml of release medium in dialysis tubing was immersed in 30.0 ml of the release medium, and oscillated with a shaker at a rate of 150 times per minute at 37 °C. A volume of 0.5 ml release medium was taken at 0, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24 and 48 h, respectively, and immediately replaced with the same volume of fresh release medium after each sampling. The irinotecan content in the release medium was determined by fluorospectrophotometer as above. The release rate was calculated with the formula: $RR = \left(\frac{W_i}{W_{\text{total}}}\right) \times 100\%$, where $RR$ is the drug release rate (%), $W_i$ is the measured amount of irinotecan at the time-point of $i$th h in release medium, and $W_{\text{total}}$ is the total amount of irinotecan in the equal volume of liposome suspensions prior to dialysis20.

The particle sizes and zeta potential values of all nanovesicles were measured with Zetasizer 3000HSA (Malvern Instruments Ltd., Malvern, Worcestershire, UK).

Culture of MDA-MB231 Cells

The culture medium was prepared with DMEM (Sigma-Aldrich Corporation, Beijing local agent, China) supplemented with 10% heat-inactivated fetal bovine serum (Sigma-Aldrich Corporation, Beijing local agent, China), 100 units/ml penicillin (Sigma-Aldrich Corporation, Beijing local agent, China), and 100 units/ml streptomycin (Sigma-Aldrich Corporation, Beijing local agent, China). The cells were cultured in the incubator at 37°C and in the presence of 5% CO₂.

Cytotoxicity to MDA-MB231 Cells

MDA-MB231 cells were seeded into 96-well culture plates at a density of 9.0×10³ cells per well
and grown in culture medium in the incubator at 37°C and in the presence of 5% CO₂ for 24 h. Free irinotecan (0-5 µM), PEG-coated irinotecan liposomes (0-5 µM) and PEG-coated irinotecan cationic liposomes (0-5 µM) were added into 96-well culture plates, respectively. The survival rate was measured at 48 h by the sulforhodamine B (SRB) staining assay, and the absorbance was read on a microplate reader at 540 nm. The survival percentages were calculated using the following formula: 
\[
\text{Survival \%} = \left( \frac{A_{540 \text{nm}} \text{ for the treated cells}}{A_{540 \text{nm}} \text{ for the control cells}} \right) \times 100\%
\]
where \( A_{540 \text{nm}} \) is the absorbance value. Each assay was repeated in triplicate. Finally, the dose-effect curves were plotted.

**Animals**

For each optimized PEG-coated irinotecan cationic liposomes studied, female BALB/c nude mice and Sprague-Dawley (SD) rats were obtained from Vital Laboratory Animal Center of Hebei Medical University. All of the animal experiments adhered to the principles for care and use of laboratory animals and were approved by the institutional Animal Care and Use Committee of Hebei Medical University.

**In vivo Inhibition of the Tumor Growth and Effects on the Indicators of Bone Marrow**

Female BALB/c nude mice, initially weighing 18-20 g, were used for investigating the antitumor efficacy *in vivo*. Briefly, approximately 2.0×10⁷ MDA-MB231 cells were resuspended in 100 µl of serum-free medium, and injected subcutaneously into the right flanks of the nude mice. When tumors reached 100 to 150 mm³ in volume, mice were randomly divided into four treatment groups (6 for each group). At day 19, 22, 25, and 28 post inoculation, physiological saline (blank control), free irinotecan (20.00 mg/kg), PEG-coated irinotecan liposomes (20.00 mg/kg), and PEG-coated irinotecan cationic liposomes (20.00 mg/kg) were given intravenously to mice which had been randomly divided into four treatment groups (6 for each group). At day 19, 22, 25, and 28 post inoculation, physiological saline (blank control), free irinotecan (20.00 mg/kg), PEG-coated irinotecan liposomes (20.00 mg/kg), and PEG-coated irinotecan cationic liposomes (20.00 mg/kg) were given intravenously to mice which had been randomly divided into four treatment groups (6 for each) via tail vein, respectively. The presence of each tumor mass was confirmed by necropsy at day 31 since the inoculation. Mice were weighed and tumors were measured with a caliper every one or every two days. Tumor volumes were calculated with the formula (length × width³/2).

At day 31, the mice were sacrificed. Blood specimens of the mice were collected immediately. The blood specimens were used for measuring the indicators of bone marrow in peripheral blood (white blood cells, WBC; hemoglobin, Hb; platelet, PLT).

**Pharmacokinetics and Tissue Distribution**

Female Sprague-Dawley (SD) rats were used for investigating the pharmacokinetics and randomly divided into three groups (6 for each group). Free irinotecan (20.00 mg/kg), PEG-coated irinotecan liposomes (20.00 mg/kg) and PEG-coated irinotecan cationic liposomes (20.00 mg/kg) were given intravenously to rats via tail vein, respectively. After administrations, a 1ml volume of plasma was collected in a heparinized microcentrifuge tube from retro orbital sinus at the
following time points: 15 min, 30 min, 1h, 2h, 4h, 8h, 12h, 24h and 48h. The plasma was separated by centrifugation at 12,000 rpm for 10 min and stored at −20°C. A 3.0-ml volume of methanol was added to the 100 μl plasma and mixed for 3 min with a vortex, followed by centrifugation at 10,000 rpm for 5 min. The liquid phase was transferred to a clean tube and dried under a gentle N₂ gas stream to obtain residues containing the irinotecan. The irinotecan residue was reconstituted with 100 μl mobile phase and centrifuged at 10,000 rpm for 5 min. Finally, a 20 μl volume of supernatant was injected into the HPLC system.

Female BALB/c nude mice were used for investigating the tissue distribution after xenografting MDA-MB231 breast cancer cells and randomly divided into three groups (6 for each group). Free irinotecan (20.00 mg/kg), PEG-coated irinotecan liposomes (20.00 mg/kg) and PEG-coated irinotecan cationic liposomes (20.00 mg/kg) were given intravenously to mice via tail vein, respectively. After administration, heart, liver, spleen, lung, kidney and tumor were also collected at 1h, 4h, 8h, 24h and 48h after sacrifice by cervical dislocation. The tissues were washed with physiological saline, dried with filter paper, weighted accurately and stored at −20°C. The tissue samples were homogenized with a homogenizer in physiological saline. A 3.0-ml volume of methanol was added to 100 μl tissue homogenate (0.15 g of tissue) and mixed for 3 min with a vortex, followed by centrifugation at 10,000 rpm for 5 min. The liquid phase was transferred to a clean tube and dried under a gentle N₂ gas stream to obtain residues containing the irinotecan. The irinotecan residue was reconstituted with 100 μl mobile phase and centrifuged at 10,000 rpm for 5 min. Finally, a 20 μl volume of supernatant was injected into the HPLC system.

The samples were analyzed by HPLC with fluorescence detection (Waters Technologies Inc., Cotati, CA, USA). Irinotecan was separated by a Diamonsil C₁₈ column (200×4.6 mm, 5 μm). The mobile phase consisted of acetonitrile and water containing 2.1% citric acid and 0.2% triethylamine (40/60, v/v) with a flow rate of 1.0 ml/min under isocratic conditions. pH was 3.8 settled by 30% natrium hydroxydatum. The fluorescence detection was set at λₑₓ 370 nm and λₑₘ 530 nm.

Statistical Analysis

Data are presented as the mean ± standard deviation. One-way analysis of variance was used to determine significance among groups, after which post hoc tests with the Bonferroni correction were used for multiple comparisons between individual groups. A value of p < 0.05 was considered to be significant.

Results

Characterization of PEG-coated Irinotecan Cationic Liposomes

Table I represents the characterization results of two liposomes. In two kinds of liposomes prepared, the encapsulation efficiency of irinotecan was ≥ 90%. The mean particle sizes of PEG-coated irinotecan liposomes and PEG-coated irinotecan cationic liposomes were 68.65 ± 5.19 and 66.32 ± 3.06 nm (Figure 1B), respectively. Their corresponding potential val-

<table>
<thead>
<tr>
<th>1. Encapsulation efficiency of irinotecan</th>
<th>Results (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PEG-coated irinotecan liposomes</td>
<td>93.66 ± 3.12%</td>
</tr>
<tr>
<td>PEG-coated irinotecan cationic liposomes</td>
<td>91.39 ± 2.58%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. Size of irinotecan liposomes</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>PEG-coated irinotecan liposomes</td>
<td>Mean size (nm)</td>
</tr>
<tr>
<td>68.65 ± 5.19</td>
<td></td>
</tr>
<tr>
<td>PEG-coated irinotecan cationic liposomes</td>
<td>66.32 ± 3.06</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. Zeta potential of irinotecan liposomes</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>PEG-coated irinotecan liposomes</td>
<td>−15.19 ± 0.68 mv</td>
</tr>
<tr>
<td>PEG-coated irinotecan cationic liposomes</td>
<td>23.13 ± 0.59 mv</td>
</tr>
</tbody>
</table>

Each point represents means ± SD (n=3).
values were -15.19±0.68 mV and 23.13±0.59 mV, respectively.

Figure 1C shows the release rates of irinotecan from two different liposomes in PBS solution containing 10% serum protein oscillated at a rate of 150 times per minute at 37°C. Release rate of irinotecan from the two kinds of liposomes was negligible under the same release condition. The release rates at 48 h of irinotecan from PEG-coated irinotecan liposomes and PEG-coated irinotecan cationic liposomes were 29.92 ± 0.81% and 28.20 ± 1.36%, respectively.

**Cytotoxicity to MDA-MB231 Cells**

Figure 2A shows the inhibitory effects to MDA-MB231 cells after applying various formulations. As compared to free irinotecan and PEG-coated irinotecan liposomes, PEG-coated irinotecan cationic liposomes showed the strongest inhibitory effects at various dose levels. For example, the rank of survival rates after applying 5 µM irinotecan were PEG-coated irinotecan liposomes (23.77 ± 1.43%) > free irinotecan (5.57 ± 1.14%) > PEG-coated irinotecan cationic liposomes (3.48 ± 1.01%).

![Graph](image_url)

**Figure 2.** A, Survival rates of MDA-MB-231 cells after applying various irinotecan formulations measured by SRB staining assay. Data are presented as the mean ± SD (n=3). a, p < 0.05, versus free irinotecan; b, p < 0.05, versus PEG-coated irinotecan liposomes. B, MDA-MB-231 cellular uptakes after applying various irinotecan formulations measured by FAScan flow cytometry. Notes: a, PBS; b, PEG-coated irinotecan liposomes; c, PEG-coated irinotecan cationic liposomes.
Intracellular Uptake of PEG-coated Irinotecan Liposomes

Figure 2B shows semi-quantitative drug content observed by flow cytometry in the MDA-MB-231 cells after applying PEG-coated irinotecan liposomes and PEG-coated irinotecan cationic liposomes at 5 h.

In quantitative evaluation for ten thousands of events, the geometric mean intensity value was 8.62 for PBS (a) < 15.36 for PEG-coated irinotecan liposomes (b) < 22.19 for PEG-coated irinotecan cationic liposomes (c).

Morphology of Nuclei Induced by PEG-Coated Irinotecan Cationic Liposomes

Figure 3 shows images for nuclei of MDA-MB-231 cells after applying free irinotecan, PEG-coated irinotecan liposomes and PEG-coated irinotecan cationic liposomes.

After applying PEG-coated irinotecan cationic liposomes, nuclei of MDA-MB231 cells became broken and evident fragment occurred as early as 6 h, showing characteristics of nuclei as MDA-MB231 breast cancer cells death. As compared to free irinotecan and PEG-coated irinotecan liposomes, PEG-coated irinotecan cationic liposomes showed the strongest inhibition effect of MDA-MB231 cancer cells.

In vivo Inhibition of the Tumor Growth and Effects on the Indicators of Bone Marrow

Figure 4A shows the efficacy of PEG-coated irinotecan cationic liposomes in treating the MDA-MB231 cells xenografts tumor model. After inoculation of MDA-MB231 cells in nude mice, the tumors reached suitable masses for treatment at day 19. As compared to blank control group, the inhibitory effects of tumor growth were obviously observed in all treatment groups. The rank of inhibitory effects was PEG-coated irinotecan cationic liposomes > PEG-coated irinotecan liposomes > free irinotecan > the blank control.
Figure 4. A, Effect of PEG-coated irinotecan cationic liposomes on the MDA-MB-231 cells xenografts in female nude mice. At day 19, 22, 25 and 28 after inoculation, physiological saline as control group, free irinotecan (20.00 mg/kg), PEG-coated irinotecan liposomes (20.00 mg/kg), and PEG-coated irinotecan cationic liposomes (20.00 mg/kg) were given intravenously to mice via tail vein, respectively. Data are presented as the mean ± SD (n=6). a, p < 0.05, versus physiological saline; b, p < 0.05, versus free irinotecan; c, p < 0.05, versus PEG-coated irinotecan liposomes. B, Body weight changes for the tumor-bearing mice after intravenous administration of physiological saline, free irinotecan, PEG-coated irinotecan liposomes and PEG-coated irinotecan cationic liposomes to mice. Data are presented as the mean ± standard deviation (n=6). a, p < 0.05, versus free irinotecan; b, p < 0.05, versus PEG-coated irinotecan liposomes. C, Time course of irinotecan levels in plasma after intravenous administration of free irinotecan (20.00 mg/kg), PEG-coated irinotecan liposomes (20.00 mg/kg) and PEG-coated irinotecan cationic liposomes (20.00 mg/kg). Each point represents means ± SD (n=6). a, p < 0.05, versus PEG-coated irinotecan liposomes; b, p < 0.05, versus PEG-coated irinotecan cationic liposomes.
PEG-coated irinotecan cationic liposomes improve the therapeutic efficacy of breast cancer in animals

**Table II.** Effect on the hematological indicators of bone marrow after intravenous administration of physiological saline (blank control), free irinotecan, PEG-coated irinotecan liposomes and PEG-coated irinotecan cationic liposomes in female BALB/c nude mice.

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Blank control</th>
<th>Free irinotecan</th>
<th>PEG-coated irinotecan liposomes</th>
<th>PEG-coated irinotecan cationic liposomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>WBC (10⁹/L)</td>
<td>9.63 ± 0.53</td>
<td>6.01 ± 0.56²</td>
<td>8.59 ± 0.72²</td>
<td>9.43 ± 0.81</td>
</tr>
<tr>
<td>Hb (g/L)</td>
<td>106.33 ± 9.12</td>
<td>75.26 ± 11.13²</td>
<td>91.55 ± 10.02²</td>
<td>101.29 ± 11.23</td>
</tr>
<tr>
<td>PLT (10⁹/L)</td>
<td>988.65 ± 35.69</td>
<td>633.61 ± 48.12²</td>
<td>901.31 ± 57.42²</td>
<td>971.32 ± 39.61</td>
</tr>
</tbody>
</table>

Data are presented as means ± SD (n = 6). WBC: white blood cell; Hb: hemoglobin; PLT: platelets. *p < 0.05, versus blank control.

Figure 4B shows the body weight changes of the tumor-bearing mice during the study of antitumor efficacy. In view of results observed in all treatment groups, body weight loss was not observed significantly in the mice after giving PEG-coated irinotecan cationic liposomes but found in the mice after giving PEG-coated irinotecan liposomes and free irinotecan.

Table II shows the effects of various formulations on the hematological indicators of bone marrow. After administration of PEG-coated irinotecan cationic liposomes, the levels of WBC, Hb, and PLT in blood specimens were slightly decreased, but without significant difference as compared to those in control group. After administration of PEG-coated irinotecan liposomes, the levels of WBC, Hb, and PLT in blood specimens were decreased. However, the levels of WBC, Hb, and PLT were severely lowered after administration of free irinotecan.

**Pharmacokinetics of Irinotecan in Plasma**

After administration of free irinotecan, the plasma irinotecan level dropped rapidly. While after administration of PEG-coated irinotecan liposomes and PEG-coated irinotecan cationic liposomes, the plasma irinotecan concentration decreased relatively slowly in the initial phase and remained at higher concentration levels in the terminal phase (Figure 4C), resulting in longer blood exposure.

The pharmacokinetic parameters were calculated according to a two-compartment model (Table III). The order of AUC in plasma was: PEG-coated irinotecan cationic liposomes (312.93±62.49 µg·h·ml⁻¹) ≥ PEG-coated irinotecan liposomes (299.79±58.91 µg·h·ml⁻¹) > free irinotecan (8.97 ± 2.73 µg·h·ml⁻¹). With respect to the elimination half-life in the terminal phase, the rank order of t₁/₂ β values in plasma was: PEG-coated irinotecan cationic liposomes (21.71 ± 5.41h⁻¹) ≥ PEG-coated irinotecan liposomes (19.66 ± 6.35h⁻¹) > free irinotecan (13.29 ± 6.94h⁻¹). The t₁/₂ α value of PEG-coated irinotecan cationic liposomes was longer than that of free irinotecan but similar to that of PEG-coated irinotecan liposomes. The Cₘₐₓ and MRT value of free irinotecan were significantly decreased relative to PEG-coated irinotecan liposomes and PEG-coated irinotecan cationic li-

**Table III.** Pharmacokinetics of irinotecan after intravenous administration of free irinotecan, PEG-coated irinotecan liposomes and PEG-coated irinotecan cationic liposomes in female rats at a dose of 20.00 mg/kg.

<table>
<thead>
<tr>
<th>Pharmacokinetic parameters</th>
<th>Free irinotecan</th>
<th>PEG-coated irinotecan liposomes</th>
<th>PEG-coated irinotecan cationic liposomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>t₁/₂ α (h)</td>
<td>1.65 ± 0.82</td>
<td>1.93 ± 0.22</td>
<td>1.88 ± 0.39</td>
</tr>
<tr>
<td>t₁/₂ β (h)</td>
<td>13.29 ± 6.94</td>
<td>19.66 ± 6.35</td>
<td>21.71 ± 5.41</td>
</tr>
<tr>
<td>Cₘₐₓ (µg/ml)</td>
<td>0.91 ± 0.33</td>
<td>89.52 ± 18.33</td>
<td>93.26 ± 20.03</td>
</tr>
<tr>
<td>CL (ml/h/kg)</td>
<td>1.85 ± 0.29</td>
<td>0.05 ± 0.01</td>
<td>0.04 ± 0.01</td>
</tr>
<tr>
<td>MRTₜ₀⁻₄₈h (h)</td>
<td>9.85 ± 3.51</td>
<td>14.22 ± 0.68</td>
<td>15.86 ± 1.12</td>
</tr>
<tr>
<td>AUC₀⁻₄₈h (µg·h/ml)</td>
<td>8.97 ± 2.73</td>
<td>299.79 ± 58.91</td>
<td>312.93 ± 62.49</td>
</tr>
</tbody>
</table>

Data are presented as means ± SD (n = 6). t₁/₂ α (h), distribution half life; t₁/₂ β (h), elimination half life; Cₘₐₓ, peak concentration; CL (ml/h/kg), total body clearance; MRTₜ₀⁻₄₈h, mean residence time; AUC₀⁻₄₈h (µg·h/ml), area under the plasma concentration-time curve.
osomes. But the CL value of free irinotecan was higher than those of PEG-coated irinotecan liposomes and PEG-coated irinotecan cationic liposomes.

**Tissue Distribution of Irinotecan**

Figure 5 and Table IV present the irinotecan levels in heart, liver, spleen, lung, kidney and tumor after intravenous administration of free irinotecan, PEG-coated irinotecan liposomes and PEG-coated irinotecan cationic liposomes at 1.0 h, 4.0 h, 8.0 h, 24 h and 48 h.

In heart, lung and kidney tissues, the irinotecan levels were approximately similar treated with free irinotecan, PEG-coated irinotecan liposomes and PEG-coated irinotecan cationic liposomes. But in liver and spleen tissue, the irinotecan level was lower in animals treated with PEG-

![Figure 5.](image)

Figure 5. Irinotecan level in heart (A), liver (B), spleen (C), lung (D), kidney (E) and tumor (F) after intravenous injection of free irinotecan, PEG-coated irinotecan liposomes and PEG-coated irinotecan cationic liposomes in female BALB/c nude mice. Each point represents means ± SD (n = 6). a, p < 0.05, versus PEG-coated irinotecan liposomes; b, p < 0.05, versus PEG-coated irinotecan cationic liposomes.

Continues in the next page
PEG-coated irinotecan cationic liposomes improve the therapeutic efficacy of breast cancer in animals.

Coated irinotecan cationic liposomes and PEG-coated irinotecan liposomes than in those treated with free irinotecan. The rank order of AUC values in liver tissue was: free irinotecan (81.56±3.73 ng·h/g) > PEG-coated irinotecan cationic liposomes (55.21±2.26 ng·h/g) ≥ PEG-coated irinotecan liposomes (49.91±3.51 ng·h/g). The rank order of AUC values in spleen tissue was: free irinotecan (51.82±3.04 ng·h/g) > PEG-coated irinotecan liposomes (45.56±3.89 ng·h/g) ≥ PEG-coated irinotecan cationic liposomes (39.72±3.14 ng·h/g).

In tumor masses (Figure 5F), the irinotecan level was significantly higher in the mice treated with PEG-coated irinotecan cationic liposomes than in those treated with free irinotecan and PEG-coated irinotecan liposomes at the 4, 8, 24 and 48h time points. The rank order of AUC values in tumor was: PEG-coated irinotecan cationic liposomes (59.24±1.87 ng·h/g) > PEG-coated irinotecan liposomes (55.21±2.26 ng·h/g) ≥ PEG-coated irinotecan cationic liposomes (53.14±3.14 ng·h/g).
coated irinotecan liposomes (30.20±4.17 ng·h/g) > free irinotecan (12.49±2.08 ng·h/g).

**Discussion**

Nowadays, research into the rational delivery and targeting of pharmaceutical agents is at the forefront of projects in cancer treatment. These treatments based nanoparticles can improve the specificity and help treatment cancer that cannot be treated with traditional ways, provide more effective and more convenient routes of administration, lower therapeutic toxicity, extend the product life cycle, and ultimately reduce health-care costs.24,25 In the past few years, a number of nanoparticle-based therapeutic agents have been developed for the treatment of cancer. As a complicated therapeutic delivery system, liposome is one of the most successful nanoparticles in the market approved by FDA for the chemotherapeutic drug loading and delivery.26,27

In this study, a kind of PEG-coated irinotecan cationic liposomes was developed for treating breast cancer. Polyethylene glycol (PEG reduction DSPE) has been used widely in nanoparticle formulations as a strategy to inhibit opsonization by plasma proteins and to prolong nanoparticle plasma circulation time. The specified uptake of PEG-coated irinotecan cationic liposomes probably relies on electrostatic interaction with negatively charged target structures on MDA-MB231 breast cancer cells membrane.28 Among the cancer cells associated target structures, there are negatively charged cell surface molecules such as glycoproteins, anionic phospholipids and proteoglycans. These are potential binding sites for cationic liposomes.29,30 The selectivity of PEG-coated irinotecan cationic liposomes offers the possibility of targeted delivery of irinotecan or other therapeutic agents to tumor cells.

Results demonstrate that PEG-coated irinotecan cationic liposomes have the following physicochemical features: high encapsulation efficiency (Table I), well-distributed particle size (Figure 1B), and delayed drug release (Figure 1C). A lower drug release will be beneficial for preventing the rapid leakage during the process of delivery and blood/lymphatic circulation of PEG-coated irinotecan cationic liposomes, thereby possibly increasing the accumulation of the irinotecan into the tumor masses.

Cytotoxicity results demonstrate that the PEG-coated irinotecan cationic liposomes exhibit strong inhibitory effect to MDA-MB231 cancer cells (Figure 2A). The enhanced inhibitory effects of the PEG-coated irinotecan cationic liposomes are explained by MDA-MB231 cancer cells uptake study in which the PEG-coated irinotecan cationic liposomes are the most strongly endocytosed by MDA-MB231 cancer cells. In a semi-quantification way, flow cytometric measurement gives the relative drug content in the cancer cells. Results show that the PEG-coated irinotecan cationic liposomes evidently increase the irinotecan content in the MDA-MB231 breast cancer cells (Figure 2B).

The morphological studies demonstrate the existence of the nuclei fragment induced by PEG-coated irinotecan cationic liposomes. In view of the fluorescent microscopic images stained by chromatin dye Hoechst 33342 (Figure 3), the irinotecan binds to the topoisomerase I-DNA complex, thereby preventing re-ligation of DNA breaks resulting in the formation of irreversible double-strand breaks and existence of the nuclei fragment after applying PEG-coated irinotecan cationic liposomes, showing the change of nuclei as MDA-MB231 cancer cells death.
The inhibitory effects on tumor volume in the MDA-MB231 breast cancer cells xenografted female nude mice demonstrate that, by intravenous injection administration, the PEG-coated irinotecan cationic liposomes exhibit significantly higher antitumor activity as compared to PEG-coated irinotecan liposomes and free irinotecan (Figure 4A). As compared to free irinotecan and PEG-coated irinotecan liposomes, PEG-coated irinotecan cationic liposomes do not cause an appreciable reduction in body weight (Figure 4B).

After administering PEG-coated irinotecan cationic liposomes to the MDA-MB231 breast cancer cells xenografted female nude mice, the bone marrow indicators (WBC, Hb, and PLT) are mildly decreased, suggesting that PEG-coated irinotecan cationic liposomes may have no significant influences on bone marrow (Table II). At least, the potential myelosuppression effect may be no more than those after administering free irinotecan and PEG-coated irinotecan liposomes. Gastrointestinal toxicity (diarrhea) is frequently observed after administration of free irinotecan. It was controlled with the administration of PEG-coated irinotecan cationic liposomes and PEG-coated irinotecan liposomes.

When comparing the concentration-time profile of free irinotecan with that of PEG-coated irinotecan liposomes or PEG-coated irinotecan cationic liposomes, irinotecan blood exposure was clearly extended by the pegylated liposomes, showing a long-circulatory effect. Pegylation with PEG2000-DSPe prevents adsorption of opsonin proteins onto the surface of irinotecan liposomes, thereby prolonging the circulation time of the liposomes by avoiding rapid uptake by the reticuloendothelial system (Figure 4C).

The liver and spleen are major sites of drug metabolism and are rich in reticuloendothelial cells. No significant difference in irinotecan levels was detected between animals administered PEG-coated irinotecan cationic liposomes and those given PEG-coated irinotecan liposomes. But after administration of PEG-coated irinotecan cationic liposomes or PEG-coated irinotecan liposomes, the irinotecan level in liver and spleen tissue was lower than free irinotecan after administration. This may be explained by the pegylated liposomes escaping rapid uptake by the reticuloendothelial system in the liver and spleen (Figure 5B and C).

Administering PEG-coated irinotecan cationic liposomes resulted in higher drug concentrations in the tumor masses than the other formulations. The higher level of irinotecan in the tumor could be attributed to specificity bind of PEG-coated irinotecan cationic liposomes by electrostatic interaction (Figure 5F). Furthermore, PEG-coated irinotecan cationic liposomes demonstrate a robust anticancer activity against the tumor xenografted with MDA-MB231 breast cancer cells.

**Conclusions**

In the present work, the PEG-coated irinotecan cationic liposomes were successfully developed with high entrapped efficiency, perfect size distribution, and slow releasing. The efficacies are confirmed in vitro and in the breast tumor by xenografting MDA-MB231 breast cancer cells into female nude mice. Mechanism studies demonstrate that PEG-coated irinotecan cationic liposomes improve the circulation time of irinotecan in the blood by escaping rapid uptake by the reticuloendothelial system and specificity bind into tumor masses by electrostatic interaction with negatively charged target structures on breast cancer cells membrane, resulting in enhancing the concentration of irinotecan in tumor area and exhibiting strong inhibitory effect to breast tumor volume. The present study provides a new strategy for treatment of the breast cancer.

**Statement of Interest**

This study was funded by the Colleges and Universities in Hebei Province Science and Technology Research Project (No. ZD200907).

**Conflict of Interest**

The Authors declare that there are no conflicts of interest.

**References**


20) LEE SM, LEE OS, O’HALLORAN TV, SCHATZ GC, NGUYEN ST. Triggered release of pharmacophores from [Ni(H₂AsO₃)]⁻loaded polymer-caged nanobin enhances pro-apoptotic activity: a combined experimental and theoretical study. ACS Nano 2011; 5: 3961-3969.


24) NAGARWA RL, KANT S, SINGH PN, MATI P, PANDIT JK. Polymeric nanoparticulate system: a potential ap-
PEG-coated irinotecan cationic liposomes improve the therapeutic efficacy of breast cancer in animals.


